1Garau J, Wilson W, Wood M, Calet J. Fourth- generation cephalosporins: a review of in vitro activity, pharmacokinetics,pharmacodynamies and clinical utility[J]. Clin Microbiol Infect, 1997,3 Suppl 1:S86-S101.
3Hancock REW, bellido F. Factors involved in the enchanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother, 1992,29 (Suppl A): 1.
4Barradell LB, Bryson HM. Cefepime, a review of its antibacterial activity,pharmaeokinetie properties and therapeutic use. Durgs,1994,47(3):489.
5Wiseman LR, Lamb HM. Cefpirome: A review of its antibacterial activity, pharmacokinetic propertis and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.Drugs, 1997,54: 117-40.
6Barry AL, Brown SD, Novick WJ. In vitro activities of cefotaxime,ceftriaxone, ceftazidine, cefpirome and penicillin against streptococcus pneumonia isolates. Antimicrob Agents Chemother, 1995,39:2193-6.
7Anthony, Terrassa, Barcelona. The clinical potential of fourthgeneration cephalosporins. Diagn Microbiol Infect Dis, 1998, 31: 479-480.
9Giamarellos-Bourboulis EJ, Grecka P, Tsitsika A, et al. in-vitro activity of FK 037 (cefoselis), a noved 4 ( th ) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates. Diagn Microbiol Infect Dis,2000 ,35(3) :185-91.
